×
About 3,588 results

ALLMedicine™ IgA Nephropathy Center

Research & Reviews  1,284 results

Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glome...
https://doi.org/10.1093/ndt/gfac204
Nephrology, Dialysis, Transplantation : Official Publicat... Makita Y, Suzuki H et. al.

Jun 25th, 2022 - Galactose-deficient IgA1 (Gd-IgA1) plays a crucial role in the development of IgA nephropathy (IgAN). However, the pathological role of Gd-IgA1-containing immune complexes (ICs) and the mechanism of deposition in the mesangial region remain unclea...

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Bi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206998
Journal of Immunology Research; Fan JW, Fan Y et. al.

Jun 24th, 2022 - Kidney transplantation is the ideal treatment for end-stage renal disease (ESRD). Chronic antibody-mediated rejection (CAMR) is the main cause of graft failure. Tfh and B cells are key immune cells that play important roles in CAMR. In this study,...

Establishment of Membrane-Bound IgA1-Specific Antibody Possessing Antibody-Dependent Ce...
https://doi.org/10.1089/mab.2021.0032
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy; Yamasaki K, Kaneko E et. al.

Jun 24th, 2022 - Therapeutic agents targeting B cells, such as rituximab, have been proven to be effective in several diseases. However, since this therapy targets the whole B cell population, there are still concerns about critical adverse events. Therefore, a ne...

Assessing prognosis in IgA nephropathy.
https://doi.org/10.1016/j.kint.2022.04.018
Kidney International; Floege J, Wied S et. al.

Jun 24th, 2022 - Assessing the prognosis is essential in chronic diseases, such as IgA nephropathy. The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the "International IgAN Prediction Tool" (available at www.qxmd.com) for this. The k...

see more →

Guidelines  3 results

A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.
https://doi.org/10.1007/s10157-021-02095-8
Clinical and Experimental Nephrology; Suzuki H, Kikuchi M et. al.

Sep 27th, 2021 - A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.|2021|Suzuki H,Kikuchi M,Koike K,Komatsu H,Matsuzaki K,|diagnosis,therapy,

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Evidence-based clinical practice guidelines for IgA nephropathy 2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956709
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.

Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,

see more →

Clinicaltrials.gov  114 results

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT03762850

Jun 16th, 2022 - This is a 114-week,randomized, multicenter, double-blind, parallel-group, active-control study with an open-label extension period of up to 156 weeks, for a total duration of up to 270 weeks in patients with IgAN who have persistent overt proteinu...

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT04014335

Jun 15th, 2022 - This is a Phase 2, single arm open-label clinical study in up to 10 participants that will consist of screening period (which may include a titration of maximum dose/maximally tolerated dose of angiotensin converting enzyme (ACE) and/or angiotensi...

Atacicept in Subjects With IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT04716231

Jun 15th, 2022 - The study will assess multiple doses of atacicept vs. placebo on impact of renal function as measured by proteinuria. Safety, eGFR, serum immunoglobulins and gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 36wk doubl...

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
https://clinicaltrials.gov/ct2/show/NCT03945318

Jun 8th, 2022 - This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single asce...

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
https://clinicaltrials.gov/ct2/show/NCT04684745

Jun 8th, 2022 - This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single asce...

see more →

News  30 results

FDA OKs First Proteinuria Drug for IgA Nephropathy
https://www.medpagetoday.com/nephrology/generalnephrology/96235

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...

'Strong Evidence' Oral Steroids Slow IgA Nephropathy Progression
https://www.medscape.com/viewarticle/962639

Nov 10th, 2021 - Daily treatment of patients with IgA nephropathy with an oral glucocorticoid, methylprednisolone, led to significant reductions in the rate of kidney failure and a composite tally of adverse incident renal outcomes in a multicenter, randomized tri...

Complement Inhibitor Shows Early Promise in IgA Nephropathy
https://www.medscape.com/viewarticle/952739

Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
https://www.medscape.com/viewarticle/949579

Apr 20th, 2021 - Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobu...

Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
https://www.mdedge.com/rheumatology/article/234917/lupus-connective-tissue-diseases/severe-renal-arteriosclerosis-may
Heidi Splete

Jan 22nd, 2021 - Severe renal arteriosclerosis was associated with a ninefold increased risk of atherosclerotic cardiovascular disease in patients with lupus nephritis, based on data from an observational study of 189 individuals. Mohammed Haneefa Nizamudeen/Getty.

see more →

Patient Education  4 results see all →